4SC AG Announces Grant of US Patent for Computer-Aided Screening Method
Posted on: Tuesday, 8 June 2004, 06:00 CDT
MARTINSRIED, Germany, June 8 /PRNewswire/ -- 4SC AG, a drug discovery and development company specialising in the research and development of therapeutic agents today announced the granting of US patent No. 6,727,100. The patent describes a method to speed up the identification of biologically active, small molecule compounds.
With the help of this method, which represents a combination of computer-aided screening and data mining, active molecules are identified from very large data sets in the shortest time. First, a small subset is selected from the data set of small molecules. Subsequently, with the aid of molecular descriptors, an algorithm identifies the most active molecules from the complete data set in several cycles, taking advantage of the correlation between the molecules' biological and chemical characteristics.
The patented method forms the basis for 4SC's in silico screening method 4SCan(R). 4SCan(R) is an integral component of the 4SC technology platform and produces clear reductions in time and costs in the area of drug-related R&D. The performance of this in silico technology has been demonstrated in the development of several projects, including a great many in collaboration with biopharmaceutical companies.
"The decision of the US Patent and Trademark Office to grant this patent will see us further develop our leading position in the area of in silico screening of large molecule databases and will ensure the economic potential of this innovative approach," commented Dr. Daniel Vitt, CSO, 4SC AG.
About 4SC
4SC is a drug discovery and development company that uses its cheminformatics-based technological platform for the discovery and development of new drug candidates. By combining the disciplines of chemistry and biology with the proprietary virtual High Throughput Screening technology, 4SCan(R), the time and cost of advancing a drug candidate to the development phase can be significantly reduced. The company's therapeutic focus centres on hyperproliferative and infectious diseases. The drug candidate SC12267 for treatment of rheumatoid arthritis from 4SC's most advanced project is currently being tested in clinical Phase I. Additional research programs in disease areas of cancer, inflammation, and bacterial infections are currently at the discovery and preclinical evaluation stage. 4SC, which was founded in 1997, today employs 60 people and is based in Martinsried, near Munich, Germany.
4SC AG
CONTACT: For more information please contact: 4SC AG, Bettina vonKlitzing, Am Klopferspitz 19a, 82152 Martinsried, Germany Tel:+49-89-700-763-0 eMail: Bettina.von.Klitzing@4sc.com
Related Articles
- Alzheimer's Drug Discovery Foundation Funds PharmatrophiX to Develop Drugs to Prevent Neurodegenerative Disease
- AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
- Anti-Fungal Drug Delivery Method Created
- CEL-SCI Announces the Development and Patenting of a New Platform Technology to Treat Immune System-Based Diseases
- VCU Researchers Develop and Patent Novel Method for Measuring Blood Pressure in the Heart
- HireRight Introduces Next-Generation Drug and Health Screening Solution; Sophisticated Software Solution Facilitates Effective Management of Pre-Employment and Random Drug Testing Programs With Faster Results
- Start-Up Gets $36 Million: TetraLogic, of Malvern, is Developing Drugs That Help the Body Kill a Variety of Cancer Cells
- Commentary: Techlink- Three MD-Based Firms Develop Drugs, Knowledge to Treat Problem of Obesity
- Companies to Develop Drug to Kill E.coli
- Researchers Develop New Testing Methods for Potential Monkeypox or Smallpox Outbreak
 |
 |
User Comments (0)
RSS Feeds